Recently, Boyu Capital, Citigroup, GF Securities, and several leading private equity firms conducted a special research visit to the Sun Yat-sen University Cancer Center. The purpose was to observe firsthand the deep implementation results of YIDU TECH's (02158) collaboration with the center in medical big data and AI applications across the entire oncology care spectrum. Following the visit, Citigroup issued a research report maintaining a "Buy" rating on YIDU TECH with a target price of HK$11. The report explicitly stated that hospital AI-related budgets are expected to continue rising, and YIDU TECH's professional clinical data governance capabilities constitute a core competitive moat.
During the on-site visit at the Sun Yat-sen University Cancer Center, the hospital's IT department and management comprehensively presented the "Data Middle Platform + AI Middle Platform" architecture co-developed with YIDU TECH over many years. The deep collaboration, which began in 2015, leverages YIDU TECH's "AI Medical Brain," YiduCore. It has helped the center establish China's first T+0 real-time updated oncology big data platform, covering the full-course data of 2 million patients. The collaboration also facilitated the local, private deployment of models like DeepSeek, Tongyi Qianwen, and YIDU TECH's proprietary large language model. Through a combination of large and small models, evidence-based traceability, and supervised fine-tuning to strictly control medical hallucinations, the solution ensures data remains within the hospital's domain, allows for model replaceability, and enables controlled application deployment.
Currently, this integrated solution has fully permeated three major scenarios: clinical care, scientific research, and hospital management. An intelligent diagnosis and treatment assistant is embedded into doctors' daily workstations, supporting automatic medical record generation, treatment pathway梳理, tumor staging assessment, and intelligent研判 of medication and risks. Medical staff can independently build customized智能体 for personalized care. On the research front, the platform enables秒级 patient cohort retrieval and intelligent clinical trial recruitment, having assisted the hospital in producing over 500 high-level academic papers. AI has overall improved doctors' work efficiency by 20%-30%, reduced case report submission time from 30 minutes to 1 minute, and cumulatively saved the hospital over 80,000 hours in labor costs, establishing it as a benchmark model for intelligent construction in domestic oncology hospitals.
During the visit, institutions engaged in in-depth discussions on topics including the iteration of medical large models, growth in hospital computing budgets, industry competition格局, and commercialization pathways. Hospital representatives直言 that,区别于 traditional medical IT vendors and large internet companies, YIDU TECH's core moat lies in its deep understanding of clinical operations, long-term high-quality data governance, and AI products that贴合 real medical workflows. The approach is not about stacking "black-box" large models but creating controllable, traceable, and implementable medical intelligent applications with strong potential for replication and推广.
Citigroup promptly followed the research visit with a commentary report, maintaining its "Buy" rating and HK$11 target price for YIDU TECH. The firm is optimistic that accelerating AI adoption in domestic hospitals will drive the company's revenue growth. YIDU TECH's positive profit alert forecasts a net profit between RMB 55 million and RMB 70 million for the fiscal year ending March 31, 2026. This marks the company's first annual profit, with盈利 elasticity expected to持续释放. The newly launched evidence-based clinical intelligent agent, "Yidu Zhi Xun," is also anticipated to open new commercialization avenues.
On other news fronts, YIDU TECH's business operations have seen multiple positive developments recently. The 2026 "Shenzhen Hui Min Bao"惠民 insurance program has officially launched, with YIDU TECH serving as the primary operating platform for the fourth consecutive year, reaffirming the company's core operational strength. Simultaneously, YIDU TECH has secured several project wins: the AI Large Model Project for Beijing Cancer Hospital, the Hainan Provincial Regional Infectious Disease Surveillance and Early Warning Platform (Phase II) project valued at approximately RMB 12.89 million, the Hainan Smart Health Island Construction Project (approx. RMB 14.76 million), and the Dr. Buddy project for Singapore's largest public healthcare group (approx. RMB 12.20 million). The accelerating pace of order落地 indicates持续向好 fundamentals.
Industry analysts note that with ongoing policy support for medical AI, increasing hospital智能化 budgets, and the expansion of the普惠 health保障 market, YIDU TECH is well-positioned to持续受益 from industry tailwinds. Leveraging its data governance moat, capability in落地医疗 large models, and全场景 AI product matrix, the company is expected to enter a phase of dual improvement in both performance and valuation.
Comments